Brokers Set Expectations for Teva Pharmaceutical Industries Limited’s Q2 2025 Earnings (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research lifted their Q2 2025 earnings estimates for Teva Pharmaceutical Industries in a research note issued on Wednesday, April 17th. Zacks Research analyst R. Department now expects that the company will earn $0.57 per share for the quarter, up from their previous estimate of $0.56. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.53 EPS and FY2026 earnings at $2.70 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The firm had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion.

Several other equities analysts have also commented on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research note on Friday, March 8th. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their target price for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Finally, Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their target price for the company from $12.00 to $19.00 in a research note on Monday, February 12th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $12.86 on Thursday. Teva Pharmaceutical Industries has a one year low of $7.09 and a one year high of $14.47. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The company has a 50 day moving average price of $13.50 and a 200 day moving average price of $11.25. The firm has a market capitalization of $14.41 billion, a price-to-earnings ratio of -27.35, a price-to-earnings-growth ratio of 1.58 and a beta of 1.05.

Insider Buying and Selling

In related news, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now owns 87,125 shares of the company’s stock, valued at approximately $1,145,693.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now owns 87,125 shares of the company’s stock, valued at approximately $1,145,693.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Insiders have sold 390,738 shares of company stock valued at $5,132,766 in the last quarter. Company insiders own 0.62% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Teva Pharmaceutical Industries by 184,642.3% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after acquiring an additional 27,696,340 shares in the last quarter. Sound Shore Management Inc CT acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $80,791,000. State Street Corp grew its holdings in Teva Pharmaceutical Industries by 29.4% during the 1st quarter. State Street Corp now owns 19,564,828 shares of the company’s stock worth $172,988,000 after acquiring an additional 4,441,883 shares in the last quarter. Exor Capital LLP grew its holdings in Teva Pharmaceutical Industries by 30.3% during the 4th quarter. Exor Capital LLP now owns 15,008,389 shares of the company’s stock worth $93,903,000 after acquiring an additional 3,486,202 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in Teva Pharmaceutical Industries by 14.4% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock worth $276,000,000 after acquiring an additional 3,413,100 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.